These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 28938491)

  • 1. Inhibition of FGFR Signaling Partially Rescues Hypophosphatemic Rickets in HMWFGF2 Tg Male Mice.
    Xiao L; Du E; Homer-Bouthiette C; Hurley MM
    Endocrinology; 2017 Oct; 158(10):3629-3646. PubMed ID: 28938491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FGF23 Neutralizing Antibody Partially Improves Bone Mineralization Defect of HMWFGF2 Isoforms in Transgenic Female Mice.
    Xiao L; Homer-Bouthiette C; Hurley MM
    J Bone Miner Res; 2018 Jul; 33(7):1347-1361. PubMed ID: 29502359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FGFR Inhibitor Ameliorates Hypophosphatemia and Impaired Engrailed-1/Wnt Signaling in FGF2 High Molecular Weight Isoform Transgenic Mice.
    Du E; Xiao L; Hurley MM
    J Cell Biochem; 2016 Sep; 117(9):1991-2000. PubMed ID: 26762209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of FGFR Signaling Partially Rescues Osteoarthritis in Mice Overexpressing High Molecular Weight FGF2 Isoforms.
    Xiao L; Williams D; Hurley MM
    Endocrinology; 2020 Jan; 161(1):. PubMed ID: 31901095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets.
    Wöhrle S; Henninger C; Bonny O; Thuery A; Beluch N; Hynes NE; Guagnano V; Sellers WR; Hofmann F; Kneissel M; Graus Porta D
    J Bone Miner Res; 2013 Apr; 28(4):899-911. PubMed ID: 23129509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FGF23 Neutralizing Antibody Ameliorates Hypophosphatemia and Impaired FGF Receptor Signaling in Kidneys of HMWFGF2 Transgenic Mice.
    Du E; Xiao L; Hurley MM
    J Cell Physiol; 2017 Mar; 232(3):610-616. PubMed ID: 27306296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FGF receptor inhibitor BGJ398 partially rescues osteoarthritis-like phenotype in older high molecular weight FGF2 transgenic mice via multiple mechanisms.
    Hurley MM; Coffin JD; Doetschman T; Valera C; Clarke K; Xiao L
    Sci Rep; 2022 Sep; 12(1):15968. PubMed ID: 36153352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FGF2 High Molecular Weight Isoforms Contribute to Osteoarthropathy in Male Mice.
    Meo Burt P; Xiao L; Dealy C; Fisher MC; Hurley MM
    Endocrinology; 2016 Dec; 157(12):4602-4614. PubMed ID: 27732085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1,25-Dihydroxyvitamin D Alone Improves Skeletal Growth, Microarchitecture, and Strength in a Murine Model of XLH, Despite Enhanced FGF23 Expression.
    Liu ES; Martins JS; Raimann A; Chae BT; Brooks DJ; Jorgetti V; Bouxsein ML; Demay MB
    J Bone Miner Res; 2016 May; 31(5):929-39. PubMed ID: 26751835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nuclear isoforms of fibroblast growth factor 2 are novel inducers of hypophosphatemia via modulation of FGF23 and KLOTHO.
    Xiao L; Naganawa T; Lorenzo J; Carpenter TO; Coffin JD; Hurley MM
    J Biol Chem; 2010 Jan; 285(4):2834-46. PubMed ID: 19933269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic Effects of FGF23 c-tail Fc in a Murine Preclinical Model of X-Linked Hypophosphatemia Via the Selective Modulation of Phosphate Reabsorption.
    Johnson K; Levine K; Sergi J; Chamoun J; Roach R; Vekich J; Favis M; Horn M; Cao X; Miller B; Snyder W; Aivazian D; Reagan W; Berryman E; Colangelo J; Markiewicz V; Bagi CM; Brown TP; Coyle A; Mohammadi M; Magram J
    J Bone Miner Res; 2017 Oct; 32(10):2062-2073. PubMed ID: 28600887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of the DMP1 C-terminal fragment stimulates FGF23 and exacerbates the hypophosphatemic rickets phenotype in Hyp mice.
    Martin A; David V; Li H; Dai B; Feng JQ; Quarles LD
    Mol Endocrinol; 2012 Nov; 26(11):1883-95. PubMed ID: 22930691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of calcimimetic R568 and calcitriol in mineral homeostasis in the Hyp mouse, a murine homolog of X-linked hypophosphatemia.
    Leifheit-Nestler M; Kucka J; Yoshizawa E; Behets G; D'Haese P; Bergen C; Meier M; Fischer DC; Haffner D
    Bone; 2017 Oct; 103():224-232. PubMed ID: 28728941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered renal FGF23-mediated activity involving MAPK and Wnt: effects of the Hyp mutation.
    Farrow EG; Summers LJ; Schiavi SC; McCormick JA; Ellison DH; White KE
    J Endocrinol; 2010 Oct; 207(1):67-75. PubMed ID: 20675303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nuclear fibroblast growth factor 2 (FGF2) isoforms inhibit bone marrow stromal cell mineralization through FGF23/FGFR/MAPK in vitro.
    Xiao L; Esliger A; Hurley MM
    J Bone Miner Res; 2013 Jan; 28(1):35-45. PubMed ID: 22836867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FGF23 Regulates Wnt/β-Catenin Signaling-Mediated Osteoarthritis in Mice Overexpressing High-Molecular-Weight FGF2.
    Meo Burt P; Xiao L; Hurley MM
    Endocrinology; 2018 Jun; 159(6):2386-2396. PubMed ID: 29718273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hexa-D-arginine treatment increases 7B2•PC2 activity in hyp-mouse osteoblasts and rescues the HYP phenotype.
    Yuan B; Feng JQ; Bowman S; Liu Y; Blank RD; Lindberg I; Drezner MK
    J Bone Miner Res; 2013 Jan; 28(1):56-72. PubMed ID: 22886699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct roles for intrinsic osteocyte abnormalities and systemic factors in regulation of FGF23 and bone mineralization in Hyp mice.
    Liu S; Tang W; Zhou J; Vierthaler L; Quarles LD
    Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1636-44. PubMed ID: 17848631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrant Phex function in osteoblasts and osteocytes alone underlies murine X-linked hypophosphatemia.
    Yuan B; Takaiwa M; Clemens TL; Feng JQ; Kumar R; Rowe PS; Xie Y; Drezner MK
    J Clin Invest; 2008 Feb; 118(2):722-34. PubMed ID: 18172553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone characteristics of autosomal dominant hypophosphatemic rickets patients.
    Liu C; Ni X; Zhao Z; Qi W; Jiang Y; Li M; Wang O; Xing X; Xia W
    Bone; 2023 Feb; 167():116602. PubMed ID: 36347435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.